香港股市 將收市,收市時間:1 小時 50 分鐘

Charles River Laboratories International, Inc. (CRL)

NYSE - NYSE 延遲價格。貨幣為 USD。
加入追蹤清單
236.30+1.03 (+0.44%)
收市:04:00PM EDT
236.30 0.00 (0.00%)
收市後: 06:08PM EDT

Charles River Laboratories International, Inc.

251 Ballardvale Street
Wilmington, MA 01887
United States
781 222 6000
https://www.criver.com

版塊Healthcare
行業Diagnostics & Research
全職員工20,400

高階主管

名稱頭銜支付行使價出生年份
Mr. James C. Foster J.D.CEO, President & Chairman2.66M1951
Ms. Flavia H. PeaseCorporate Executive VP & CFO1.66M1973
Ms. Birgit GirshickCorporate Executive VP & COO1.28M464.88k1970
Mr. Joseph W. LaPlumeCorporate Executive Vice President of Corporate Development & Strategy928.36k262.98k1974
Mr. William D. BarboCorporate Executive Vice President of Community Relations1M399.92k1961
Mr. Michael Gunnar KnellCorporate Senior VP & Chief Accounting Officer1977
Prof. Julie Frearson Ph.D.Corporate Senior VP & Chief Scientific Officer
Mr. Mark MintzCorporate Senior VP & Chief Information Officer
Todd SpencerCorporate Vice President of Investor Relations
Mr. Matthew L. DanielCorporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

公司管治

截至 2024年5月1日 止,Charles River Laboratories International, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中:6;董事會:4;股東權利:8;現金賠償:5。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。